Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Bacterial Vaginosis-Pipeline Review, H1 2015

Bacterial Vaginosis-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Bacterial Vaginosis-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Bacterial Vaginosis-Pipeline Review, H1 2015', provides an overview of the Bacterial Vaginosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacterial Vaginosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bacterial Vaginosis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bacterial Vaginosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bacterial Vaginosis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bacterial Vaginosis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bacterial Vaginosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Bacterial Vaginosis Overview 6

Therapeutics Development 7

Pipeline Products for Bacterial Vaginosis-Overview 7

Pipeline Products for Bacterial Vaginosis-Comparative Analysis 8

Bacterial Vaginosis-Therapeutics under Development by Companies 9

Bacterial Vaginosis-Therapeutics under Investigation by Universities/Institutes 10

Bacterial Vaginosis-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Bacterial Vaginosis-Products under Development by Companies 14

Bacterial Vaginosis-Products under Investigation by Universities/Institutes 15

Bacterial Vaginosis-Companies Involved in Therapeutics Development 16

AmVac AG 16

Osel Inc. 17

Starpharma Holdings Limited 18

Valeant Pharmaceuticals International, Inc. 19

Bacterial Vaginosis-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Drug Profiles 25

AMV-100-Drug Profile 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

astodrimer-Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

benzoyl peroxide-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

LACTIN-V-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Peptide for Bacterial Vaginosis-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Product-55394-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

secnidazole-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Bacterial Vaginosis-Recent Pipeline Updates 33

Bacterial Vaginosis-Dormant Projects 37

Bacterial Vaginosis-Discontinued Products 38

Bacterial Vaginosis-Product Development Milestones 39

Featured News & Press Releases 39

Sep 09, 2014: Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis 39

Jul 14, 2014: FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial 40

Apr 03, 2013: Starpharma Announces Positive Results From Phase II Study Of VivaGel For Prevention Of Recurrent Bacterial Vaginosis 40

Nov 28, 2012: Starpharma Announces Results From Two Phase III Studies Of VivaGel For Treatment Of Bacterial Vaginosis 42

Oct 18, 2012: Starpharma Completes Recruitment In Two Phase III Trials Of VivaGel For Treatment For Bacterial Vaginosis 44

Jun 25, 2012: Starpharma Completes Patient Recruitment For Phase II And First Pivotal Phase III Trials Of VivaGel 44

Jun 04, 2012: Starpharma Completes 60% Patient Recruitment For Phase III Trials Of VivaGel 45

Jan 11, 2012: Starpharma Receives FDA Special Protocol Assessment For Phase III Trials Of VivaGel For Treatment Of Bacterial Vaginosis 46

Nov 21, 2011: Starpharma Secures European Agreement On BV Phase III Treatment 46

Oct 10, 2011: Starpharma Secures FDA Agreement On Phase III VivaGel Bacterial Vaginosis Treatment Program 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 49

Disclaimer 49

List of Tables

Number of Products under Development for Bacterial Vaginosis, H1 2015 7

Number of Products under Development for Bacterial Vaginosis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Products under Investigation by Universities/Institutes, H1 2015 15

Bacterial Vaginosis-Pipeline by AmVac AG, H1 2015 16

Bacterial Vaginosis-Pipeline by Osel Inc., H1 2015 17

Bacterial Vaginosis-Pipeline by Starpharma Holdings Limited, H1 2015 18

Bacterial Vaginosis-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 19

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Stage and Route of Administration, H1 2015 22

Number of Products by Stage and Molecule Type, H1 2015 24

Bacterial Vaginosis Therapeutics-Recent Pipeline Updates, H1 2015 33

Bacterial Vaginosis-Dormant Projects, H1 2015 37

Bacterial Vaginosis-Discontinued Products, H1 2015 38

List of Figures

Number of Products under Development for Bacterial Vaginosis, H1 2015 7

Number of Products under Development for Bacterial Vaginosis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Top 10 Routes of Administration, H1 2015 21

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 21

Number of Products by Top 10 Molecule Types, H1 2015 23

Number of Products by Stage and Top 10 Molecule Types, H1 2015 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AmVac AG

Osel Inc.

Starpharma Holdings Limited

Valeant Pharmaceuticals International, Inc.

Bacterial Vaginosis Therapeutic Products under Development, Key Players in Bacterial Vaginosis Therapeutics, Bacterial Vaginosis Pipeline Overview, Bacterial Vaginosis Pipeline, Bacterial Vaginosis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com